A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Inclusion Criteria

• •age:14-65 years;ECOG rate≤2;expected survival≥3 months
• •patients with Diffuse Large B cell lymphoma diagnoesd by histopathology detection;
• •patients ever received RCHOP or CHOP chemotherapy but did not receive DHAP
• •patients never received radiotherapy
• •patients with no chemotherapy contraindications:hemoglobin ≥ 90g/L,absoluate neutrophil count ≥1.5x109/L,blood platelet ≥100x109/L,ALT and AST ≤ 2-fold upper normal limit,serum bilirubin ≤1.5-fold upper normal limit,serum creatinine ≤1.5-fold upper normal limit,serum albumin ≥ 30g/L,normal serofibrinogen;
• •at least one measurable nidus;
• •no other severe diseases conflict with this project,cardiopulmonary function is basically normal
• •the urine or blood pregnancy test of women in childbearing age must be negative in 7 days before follow-up visit;
• •applicable for follow-up visit;
• •no other antitumor adjoint therapy(including antitumor Chinese medicine,immunotherapy and biotherapy),but double phosphate anti-bone transfer therapy and other symptomatic treatment are acceptable;
• •understanding this study and assigning informed consent.